OTCM
NVZMY
Market cap27bUSD
Jun 18, Last price
59.53USD
1D
1.88%
1Q
10.02%
Jan 2017
72.50%
Name
Novozymes A/S
Chart & Performance
P/E
589.43
P/S
47.02
EPS
0.66
Div Yield, %
1.65%
Shrs. gr., 5y
-0.61%
Rev. gr., 5y
-23.23%
Revenues
3.83b
-78.58%
Net income
306m
-89.89%
CFO
1.02b
-75.44%
Dividend
Sep 02, 20250.35039 USD/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Novozymes A/S, a Danish enterprise established in 1925 and headquartered in Bagsvaerd, is a leading provider of biological solutions, specializing in the production and global distribution of industrial enzymes, microorganisms, and probiotics. Its extensive reach spans across Europe, the Middle East, Africa, North America, Asia Pacific, and Latin America. The company's diverse portfolio caters to a wide array of sectors, including the food and beverage industry with innovations for baking, beverages, dairy, starch processing, and protein applications. In household care, its products enhance laundry, dishwashing, and professional cleaning. For agriculture, Novozymes supports crop production with bioyield and biocontrol technologies, alongside animal health and nutrition solutions. It also contributes to industrial processing, providing solutions for grain and technical processes, as well as bioenergy applications encompassing liquefaction, saccharification, fermentation, and the conversion of fiber and biomass. Other significant areas of focus include textile treatments (such as biopreparation, biopolishing, and denim finishing), pulp and paper production (enhancing fiber modification, bleach boosting, and deinking), and leather processing (from soaking and bating to unhairing and degreasing). Furthermore, its expertise extends to water and waste management with bioaugmentation, biogas, and sludge control technologies. Additionally, Novozymes plays a role in pharmaceuticals, offering lipases and proteases for biocatalysis and rTrypsin for cell culture, in addition to broader human health and protein-related solutions.
Valuation
Title DKK in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||